Global Patient Registry Software Strategic Business Report 2024: Market to Reach $2.4 Billion by 2027 - Disease Registries Segment to Record 12.2% CAGR
February 20, 2024 06:50 ET
|
Research and Markets
Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Patient Registry Software: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Patient Registry...
Global Patient Registry Software Market Analysis and Outlook to 2028: Dacima Software, FIGmd, Global Vision Technologies, Image Trend, and IQVIA Dominate the Landscape
January 26, 2024 09:02 ET
|
Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Patient Registry Software Market - Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028" report has been added to ...
Global Patient Registry Software Market is set to grow at a CAGR of 11-14% by 2027 - Transforming Healthcare Information System
May 15, 2023 10:00 ET
|
Medi-Tech Insights
BRUSSELS, BELGIUM, May 15, 2023 (GLOBE NEWSWIRE) -- A patient registry is an organized system to collect uniform data from a group of individuals who share a common disease or treatment. It is a...
Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry: for people affected by pelvic radiation during cancer treatment
May 10, 2022 15:27 ET
|
Lipella Pharmaceuticals, Inc.
Pittsburgh, Pennsylvania, United States , May 10, 2022 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program...
Global Patient Registry Software Market to Double in Size from $1.4 Billion in 2021 to $2.8 Billion by 2026
November 12, 2021 07:28 ET
|
Research and Markets
Dublin, Nov. 12, 2021 (GLOBE NEWSWIRE) -- The "Patient Registry Software Market by Type of Registry (Diabetes, Cancer, Rare Disease, Asthma, Kidney), Software (Integrated and Standalone), Delivery...
Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
March 02, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, March 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...